TAMIFLU 45 MG
OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) : 45 MG · DIN 02304856 · HOFFMANN-LA ROCHE LIMITED
Health Canada status: MARKETED
What is TAMIFLU?
TAMIFLU 45 MG contains OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) : 45 MG. It is listed in the Health Canada Drug Product Database under DIN 02304856, held by HOFFMANN-LA ROCHE LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 08-Dec-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TAMIFLU used for?
Treatment of uncomplicated acute illness due to influenza in patients ≥1 year symptomatic for ≤2 days. Prevention of influenza in patients ≥1 year following close contact with an infected individual.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02304856 |
|---|---|
| Brand name | TAMIFLU |
| Generic / active ingredient | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) : 45 MG |
| Manufacturer | HOFFMANN-LA ROCHE LIMITED |
| Strength | 45 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AH02 OSELTAMIVIR |
| AHFS class | 08:18.28 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 08-Dec-2008 |
| Original market date | 2008-12-08 00:00:00 |
How is it administered?
Treatment: 75 mg twice daily for 5 days. Prevention: 75 mg once daily for at least 10 days. Start within 2 days of symptom onset or exposure. Adjust dose for renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Reconstituted suspension: 10 days at room temperature (≤25°C) or 17 days in a refrigerator (2-8°C).
How is it supplied?
Capsules (30 mg, 45 mg, 75 mg) and powder for oral suspension (6 mg/mL when reconstituted). Specific bottle sizes for suspension include 390 mg oseltamivir (65 mL total).
Contraindications
Hypersensitivity to oseltamivir phosphate or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Not a substitute for influenza vaccination. Efficacy not established in patients starting treatment after 40 hours of symptoms. Not effective for respiratory infections other than influenza.
What can be used instead?
Other Canadian products sharing ATC code J05AH02 OSELTAMIVIR. 15 of 31 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP OSELTAMIVIR | 30 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02497409 |
| JAMP OSELTAMIVIR | 75 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02497425 |
| MINT-OSELTAMIVIR | 30 MG | CAPSULE | MINT PHARMACEUTICALS INC | MARKETED | DIN 02497441 |
| MINT-OSELTAMIVIR | 75 MG | CAPSULE | MINT PHARMACEUTICALS INC | MARKETED | DIN 02497476 |
| NAT-OSELTAMIVIR | 30 MG | CAPSULE | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02472635 |
| NAT-OSELTAMIVIR | 45 MG | CAPSULE | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02472643 |
| NAT-OSELTAMIVIR | 6 MG | POWDER FOR SUSPENSION | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02499894 |
| NAT-OSELTAMIVIR | 75 MG | CAPSULE | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02457989 |
| SANDOZ OSELTAMIVIR | 30 MG | CAPSULE | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02504006 |
| SANDOZ OSELTAMIVIR | 45 MG | CAPSULE | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02504014 |
Who else supplies OSELTAMIVIR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OSELTAMIVIR appears in 55 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.